Molecular mechanisms for chronic opioid actions has not been fully elucidated yet. Earlier reported studies, using clonal cell line models, suggested probable cellular modification of the receptor. Chronic administration of opioid agonists in vitro to tissue culture cells, such as neuroblastoma x glioma NG108-15, or in vivo to animals, have resulted in an alteration of the steady state level of opioid receptor. Previous efforts to determine how neuronal cells regulate opioid receptor level during chronic agonist exposure have been hampered by the lack of receptor reagents, such as receptor specific antibodies or the cDNA clone of the receptor. Such problems have been alleviated by recent reports of the cloning of three major types of opioid receptors, mu-, delta- and kappa- opioid receptors. We have since developed delta-opioid receptor specific polyclonal antibodies, using the peptide sequences specific for delta- opioid receptor and have designed delta-opioid receptor specific oligodeoxynucleotides that they have been used successfully in quantitating the level of the delta-opioid receptor messages in NG108-15 cells. Thus, with these reagents, we could now examine how neuronal cells, such as neuroblastoma x glioma cells control the steady state level of the receptor. The itinerary of the delta-opioid receptor in the presence of agonist will be examined. The turnover rate of the receptor protein will be determined. Cellular components which are involved in the endocytosis and trafficking of the receptor will be determined. In addition to tracking the receptor with receptor specific antibodies, we are also developing hemagglutinin epitope tagged delta-opioid receptor utilizing commercial available monoclonal antibodies to this epitope. The receptor domains involved in the receptor internalization and trafficking to lysozomes will be determined by mutational analysis of the intracellular domains of the receptor. Cellular components tightly associated with the receptor after agonist binding, such as the small GTP- binding proteins, will be identified by isolation of the agonist-receptor complexes using immunoaffinity columns. Regulation of the receptor protein level via transcriptional and translational control will also be examined. Cellular control of receptor transcription will be investigated by quantitating the delta-opioid receptor mRNAs under various conditions. Toward understanding the transcriptional regulation, the delta-opioid receptor gene will be isolated and characterized. The 5-upstream regulation elements will be identified. Cellular control of these regulation elements' activities will be investigated. By determining the mechanism of cellular regulation of both transcript and protein levels of delta-opioid receptor, we can then begin to understand neuronal cell regulation of the steady state level of the receptor and probable involvement of these cellular events in the expression of chronic opioid effects.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA005695-09
Application #
6269985
Study Section
Project Start
1998-02-20
Project End
1999-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
9
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Choe, Chung-youl; Kim, Hogyoung; Dong, Jinping et al. (2011) The polypyrimidine/polypurine motif in the mouse mu opioid receptor gene promoter is a supercoiling-regulatory element. Gene 487:52-61
Choe, Chung-Youl; Dong, Jinping; Law, Ping-Yee et al. (2011) Differential gene expression activity among species-specific polypyrimidine/polypurine motifs in mu opioid receptor gene promoters. Gene 471:27-36
Law, P Y; Wong, Y H; Loh, H H (1999) Mutational analysis of the structure and function of opioid receptors. Biopolymers 51:440-55
Lentz, T L; Chaturvedi, V; Conti-Fine, B M (1998) Amino acids within residues 181-200 of the nicotinic acetylcholine receptor alpha1 subunit involved in nicotine binding. Biochem Pharmacol 55:341-7
Grando, S A; Horton, R M; Pereira, E F et al. (1995) A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol 105:774-81
Lei, S; Okita, D K; Conti-Fine, B M (1995) Binding of monoclonal antibodies against the carboxyl terminal segment of the nicotinic receptor delta subunit suggests an unusual transmembrane disposition of this sequence region. Biochemistry 34:6675-88
Conti-Fine, B M; Maelicke, A; Reinhardt-Maelicke, S et al. (1995) Binding sites for neurotoxins and cholinergic ligands in peripheral and neuronal nicotinic receptors. Studies with synthetic receptor sequences. Ann N Y Acad Sci 757:133-52
Law, P Y; McGinn, T M; Wick, M J et al. (1994) Analysis of delta-opioid receptor activities stably expressed in CHO cell lines: function of receptor density? J Pharmacol Exp Ther 271:1686-94
Conti-Tronconi, B M; McLane, K E; Raftery, M A et al. (1994) The nicotinic acetylcholine receptor: structure and autoimmune pathology. Crit Rev Biochem Mol Biol 29:69-123
Prather, P L; Loh, H H; Law, P Y (1994) Interaction of delta-opioid receptors with multiple G proteins: a non-relationship between agonist potency to inhibit adenylyl cyclase and to activate G proteins. Mol Pharmacol 45:997-1003

Showing the most recent 10 out of 43 publications